K C Balaji

K C Balaji, MBBS, FRCS, MRCS, LRCP

Professor; Chair, Department Of Urology; Program Director, Advanced Urology Fellowship; And Program Director, Urology Residency

Department: Urology – Jacksonville
Business Phone: (904) 244-7340

About K C Balaji

Dr. Balaji is widely known as a pioneer in the field of robotic surgery. He is highly regarded as an expert in managing advanced urological cancers of the prostate, bladder, kidney, testes and penis.

Accomplishments

Approved for Tenure
2022 · University of Florida College of Medicine – Jacksonville

Teaching Profile

Courses Taught
2018
PAS5270 Urology

Board Certifications

  • Urology
    American Board of Urology

Clinical Profile

Specialties
  • Urology

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0002-8057-2839

Publications

2023
Does care fragmentation in patients with bladder cancer lead to worse outcomes?
Urologic Oncology: Seminars and Original Investigations. [DOI] 10.1016/j.urolonc.2022.10.028.
2022
3JC48-3 (methyl 4′-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1′-biphenyl]-3-carboxylate): a novel MYC/MAX dimerization inhibitor reduces prostate cancer growth
Cancer Gene Therapy. 29(11):1550-1557 [DOI] 10.1038/s41417-022-00455-4.
2022
Diagnostic accuracy of vesical imaging-reporting and data system (VI-RADS) in suspected muscle invasive bladder cancer: A systematic review and diagnostic meta-analysis.
Urologic oncology. 40(2):45-55 [DOI] 10.1016/j.urolonc.2021.11.008. [PMID] 34895996.
2022
The Geriatric Nutritional Risk Index Predicts Postoperative Outcomes in Bladder Cancer: A Propensity Score-Matched Analysis.
The Journal of urology. 207(4):797-804 [DOI] 10.1097/JU.0000000000002342. [PMID] 34854753.
2021
An Indirect Comparison of Newer Minimally Invasive Treatments for Benign Prostatic Hyperplasia: A Network Meta-Analysis Model.
Journal of endourology. 35(4):409-416 [DOI] 10.1089/end.2020.0739. [PMID] 32962442.
2021
Intracorporeal versus extracorporeal urinary diversion following robot-assisted radical cystectomy: a meta-analysis, cumulative analysis, and systematic review.
Journal of robotic surgery. 15(3):321-333 [DOI] 10.1007/s11701-020-01174-4. [PMID] 33222043.
2021
MRI and CT bladder segmentation from classical to deep learning based approaches: Current limitations and lessons.
Computers in biology and medicine. 134 [DOI] 10.1016/j.compbiomed.2021.104472. [PMID] 34023696.
2021
Pathology grade influences competing mortality risks in elderly men with prostate cancer.
Urologic oncology. 39(8):493.e1-493.e7 [DOI] 10.1016/j.urolonc.2020.12.004. [PMID] 33353870.
2021
Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: What about the Negatives?
Radiology. 298(1) [DOI] 10.1148/radiol.2020202870. [PMID] 33141006.
2020
A Systematic Review and Meta-Analysis of Methods Used to Reduce Infectious Complications Following Transrectal Prostate Biopsy.
Urology. 144:21-27 [DOI] 10.1016/j.urology.2020.06.005. [PMID] 32569659.
2020
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
Urologic oncology. 38(11):826-834 [DOI] 10.1016/j.urolonc.2020.03.022. [PMID] 32605736.
2020
Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia.
International urology and nephrology. 52(6):999-1008 [DOI] 10.1007/s11255-020-02408-y. [PMID] 32065331.
2020
Re: Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-AnalysisA. Pilatz, K. Dimitropoulos, R. Veeratterapillay, Y. Yuan, M. I. Omar, S. MacLennan, T. Cai, F. Bruyère, R. Bartoletti, B. Köves, F. Wagenlehner, G. Bonkat and B. Pradere J Urol 2020; 204: 224-230.
The Journal of urology. 204(6):1349-1350 [DOI] 10.1097/JU.0000000000001332. [PMID] 32830995.
2020
Symptomatic Pituitary Metastasis as Initial Manifestation of Renal Cell Carcinoma: Case Report and Review of Literature.
Case reports in endocrinology. 2020 [DOI] 10.1155/2020/8883864. [PMID] 32908722.
2017
Beta-catenin represses protein kinase D1 gene expression by non-canonical pathway through MYC/MAX transcription complex in prostate cancer.
Oncotarget. 8(45):78811-78824 [DOI] 10.18632/oncotarget.20229. [PMID] 29108267.
2013
Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy.
Journal of endourology. 27(8):1046-50 [DOI] 10.1089/end.2012.0606. [PMID] 23517015.
2010
Robotic partial cystectomy for bladder cancer: a single-institutional pilot study.
Journal of endourology. 24(2):223-7 [DOI] 10.1089/end.2009.0367. [PMID] 20039797.
2006
Comparative analysis of early perioperative outcomes following radical cystectomy by either the robotic or open method.
JSLS : Journal of the Society of Laparoendoscopic Surgeons. 10(2):145-50 [PMID] 16882409.
2006
Metallothioneins and resistance to cisplatin and radiation in prostate cancer.
Urology. 67(6):1341-7 [PMID] 16765200.
2005
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
Urologic oncology. 23(6):402-6 [PMID] 16301117.
2005
Feasibility of robotic radical nephrectomy–initial results of single-institution pilot study.
Urology. 65(6):1086-9 [PMID] 15913733.
2005
Robotic transperitoneal detrusor myotomy: description of a novel technique.
Journal of endourology. 19(4):476-9 [PMID] 15910260.
2005
Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer.
Urologic oncology. 23(6):407-12 [PMID] 16301118.
2004
Feasibility of robot-assisted totally intracorporeal laparoscopic ileal conduit urinary diversion: initial results of a single institutional pilot study.
Urology. 63(1):51-5 [PMID] 14751347.
2004
Microarray analysis of differential gene expression in androgen independent prostate cancer using a metastatic human prostate cancer cell line model.
Urologic oncology. 22(4):313-20 [PMID] 15283889.
2002
Laparoscopic vasectomy: case report and review of the literature.
Journal of endourology. 16(2):105-6 [PMID] 11962550.
2000
Concordant prune belly syndrome in monozygotic twins.
Urology. 55(6) [PMID] 10840120.
1999
Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance.
The Journal of urology. 162(3 Pt 1):753-7 [PMID] 10458359.
1999
Upper tract recurrences following radical cystectomy: an analysis of prognostic factors, recurrence pattern and stage at presentation.
The Journal of urology. 162(5):1603-6 [PMID] 10524877.
1997
Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer.
Urology. 50(6):1007-15 [PMID] 9426742.
1995
Laparoscopic diagnosis and management of transverse testicular ectopia.
Urology. 46(6):879-80 [PMID] 7502436.

Grants

Aug 2021 ACTIVE
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Role: Principal Investigator
Funding: PPD INVESTIGATOR SERVICES LLC via JANSSEN RESEARCH AND DEVELOPMENT
Feb 2021 ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Jul 2020 ACTIVE
Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN Registry)
Role: Principal Investigator
Funding: PROSTATE CANCER CLINICAL TRIALS CONS
Dec 2019 ACTIVE
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Sep 2019 ACTIVE
COMBINATORIAL INHIBITION OF MYC IN PROSTATE CANCER
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Feb 2019 ACTIVE
The collection of whole blood and other human bio-fluid specimens from subjects clinically diagnosed with cancer and/or other related disease.
Role: Principal Investigator
Funding: DISCOVERY LIFE SCIENCES
Jan 2019 ACTIVE
ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL CORP via CONSTELLATION PHARMACEUTICALS

Education

Urologic Oncology Fellowship
1997-1999 · Memorial Sloan-Kettering Cancer Center, New York, NY
Urology Residency
1993-1997 · University of Massachusetts Medical Center, Worcester, MA
Medical Degree
1982-1986 · Madras Medical College, Park Town, India

Contact Details

Phones:
Business:
(904) 244-7340
Addresses:
Business Mailing:
653 W 8TH ST
JACKSONVILLE FL 32209